Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-508F]

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020

AGENCY:

Drug Enforcement Administration, Department of Justice.

ACTION:

Final order.

SUMMARY:

This final order establishes the final adjusted 2020 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES:

This order is effective December 1, 2020.

FOR FURTHER INFORMATION CONTACT:

Scott A. Brinks, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (571) 362-3261.

SUPPLEMENTARY INFORMATION:

Legal Authority

Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas (APQ) for each basic class of controlled substances listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the Drug Enforcement Administration (DEA) pursuant to 28 CFR 0.100.

Background

DEA published the 2020 established APQ for controlled substances in schedules I and II and for the assessment of annual needs (AAN) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the

Federal Register

on December 2, 2019. 84 FR 66014. DEA is committed to preventing and limiting diversion by enforcing laws and regulations regarding controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, while meeting the legitimate medical, scientific, and export needs of the United States. This notice stated that the Administrator would adjust, as needed, the established APQ in 2020 in accordance with 21 CFR 1303.13 and 21 CFR 1315.13.

In response to the public health emergency declared by the Secretary of Health and Human Services (HHS) on January 31, 2020, DEA published the final order titled “Adjustments to Aggregate Production Quotas for Certain Schedule II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine and Pseudoephedrine for 2020” on April 10, 2020. (85 FR 20302). While the adjustments were effective immediately, all interested persons were invited to comment on or object to the adjustments on or before May 11, 2020.

The 2020 proposed adjusted APQ for controlled substances in schedules I and II and AAN for the list I chemicals

ephedrine, pseudoephedrine, and phenylpropanolamine were subsequently published in the

Federal Register

on September 1, 2020, (85 FR 54414), after consideration of the criteria outlined in that notice. All interested persons were invited to comment on or object to the proposed APQs and AANs on or before October 1, 2020.

Comments Received

DEA received five timely comments and one untimely comment in response to the April

Federal Register

notice and nine comments in response to the September

Federal Register

notice from patients, DEA-registered entities, and non-DEA entities. The comments included appreciation of DEA's response to the public health emergency, concerns about potential drug shortages, interference with doctor-patient relationships, and comments outside the scope of this final order.

Issue:

Commenters expressed appreciation of DEA's flexibility in responding to the nationwide public health emergency declared by the Secretary of HHS on January 31, 2020, by adjusting APQ for select schedule II controlled substances and list I chemicals.

DEA Response:

DEA acknowledges the expressions of appreciation to changes in the APQ and AAN. The adjustments to select schedule II controlled substances and list I chemicals occurred after DEA consulted with HHS and determined the utilization rates for these drugs substantially increased due to the treatment regimens for ventilator patients stricken with the Coronavirus Disease of 2019 (COVID-19) compared to the previously estimated annual consumption rates. While the estimates from HHS provided a wide range in the number of patients that would require ventilation treatment due to COVID-19, DEA could, under 21 CFR 1303.13 and 1315.13, adjust the APQ and AAN for schedule II controlled substances and list I chemicals, respectively, to ensure manufacturing activities cover the upper range of the estimate could occur in a timely manner. DEA highlights factor 21 CFR 1303.13(b)(5) specifically, which allowed the Acting Administrator to increase the APQ and AAN for select controlled substances and list I chemicals to meet additional estimated medical needs as determined by HHS due to the unforeseen emergency caused by the COVID-19 pandemic.

Issue:

Commenters expressed general concerns that decreasing the APQ of controlled substances could lead to shortages of controlled substance medications.

One DEA-registered entity submitted a comment requesting the APQ for hydrocodone (for sale) and oxycodone (for sale) be sufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements, and for the establishment and maintenance of reserve stocks.

DEA Response:

DEA sets APQ in a manner to ensure that the estimated medical, scientific, research, industrial needs of the United States, lawful export requirements, and for the establishment and maintenance of reserve stocks. As discussed in both notices for adjustments, any adjustments to the APQ for controlled substances is based on factors set forth in 21 CFR 1303.13. In the event of a shortage, the CSA provides a mechanism under which DEA will, in appropriate circumstances, increase quotas to address shortages. 21 U.S.C. 826(h). Under 21 U.S.C. 826(h)(1), after receiving a request to address a shortage, DEA has 30 days to complete review of the request and determine whether adjustments are necessary to address the shortage. If adjustments are necessary, DEA is required to increase the APQ and individual production quotas to alleviate the shortage.

Id.

If DEA determines adjustments are not necessary, DEA is required to “provide a written response detailing the basis for the . . . determination.”

Id.

In addition to what Section 826(h)(1) requires, when DEA is notified of an alleged shortage, DEA will confer with the U.S. Food and Drug Administration and relevant manufacturers regarding the amount of material in physical inventory, current quota granted, and the estimated legitimate medical need, to determine whether a quota adjustment is necessary to alleviate any factually valid shortage.

In accordance with 21 CFR 1303.13, DEA considered the comments for hydrocodone (for sale) and oxycodone (for sale), and the Acting Administrator determined the proposed adjusted 2020 APQs for these substances as published in the

Federal Register

on September 1, 2020, (85 FR 54414), are sufficient to meet the current 2020 estimated medical, scientific, research, and industrial needs of the United States, and to provide for adequate reserve stock.

Issue:

DEA received comments of general concerns alleging decreases to the APQ interfered with doctor-patient relationships.

DEA Response:

In determining the APQ, DEA considers prescriptions that have been issued. However, DEA does not interfere with doctor-patient relationships. Doctors authorized to dispense controlled substances are responsible for adhering to the laws and regulations set forth under the CSA, which requires doctors to only write prescriptions for a legitimate medical need. DEA is responsible for enforcing controlled substance laws and regulations, and is committed to ensuring an adequate and uninterrupted supply of controlled substances in order to meet the demand of legitimate medical, scientific, and export needs of the United States.

Untimely Comment Issue:

The DEA received one comment from a DEA-registered entity for previously established value of the 2020 AAN for pseudoephedrine (for conversion), requesting an increase because the established AAN is not adequate to cover the commenter's new projected need for 2020.

DEA Response:

The comment was received in between the comment periods for the two notices of adjustment. Even though the comment was outside the comment period that ended on May 11, 2020, DEA considered this comment as part of the second comment period ending on October 1, 2020, when setting the final 2020 AAN.

Out of Scope Comments:

DEA received comments on issues outside the scope of this final order. The comments were general in nature and raised issues of specific medical illnesses, medical treatments, and medication costs, and therefore, are outside of the scope of this Final Order for 2020 and do not impact the original analysis involved in finalizing the 2020 APQ.

Analysis for Final Adjusted 2020 Aggregate Production Quotas and Assessment of Annual Needs

In determining the final adjusted 2020 APQ and AAN, DEA has considered the above comments relevant to this Final Order for calendar year 2020, along with the factors set forth in 21 CFR 1303.13 and 21 CFR 1315.13, in accordance with 21 U.S.C. 826(a). DEA has also considered other relevant factors, including the 2019 year-end inventories, initial 2020 manufacturing and import quotas, 2020 export requirements, actual and projected 2020 sales, research and product development requirements, additional applications received, and the extent of any diversion of the controlled substance in the class. Based on all of the above, the Acting Administrator is adjusting the 2020 APQ for the following: Increases for

Amphetamine (for sale) and Methamphetamine, based on the data received since the publication of the 2020 proposed adjustment for APQ and AAN in the

Federal Register

on September 1, 2020 (85 FR 54414); increases for Crotonyl Fentanyl, Ethylone, and Isotonitazene due to the publication of their schedule I temporary controlled status; and increases for Etonitazene due to additional manufacturers entering the reference standard market. This final order reflects those adjustments.

Pursuant to the above, the Acting Administrator hereby finalizes the 2020 APQ for the following schedule I and II controlled substances and the 2020 AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic class

Final revised

2020 quotas

(g)

Temporarily Scheduled Substances

Crotonyl fentanyl

25

Ethylone

25

Isotonitazene

25

Schedule I

1-[1-(2-Thienyl)cyclohexyl]pyrrolidine

20

1-(1-Phenylcyclohexyl)pyrrolidine

15

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine

10

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)

30

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)

30

1-Benzylpiperazine

25

1-Methyl-4-phenyl-4-propionoxypiperidine

10

1-[1-(2-Thienyl)cyclohexyl]piperidine

15

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)

30

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)

30

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)

30

2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)

30

2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)

100

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)

30

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)

30

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82)

25

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)

30

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)

30

2,5-Dimethoxy-4-ethylamphetamine (DOET)

25

2,5-Dimethoxy-4-(n)-propylthiophenethylamine

25

2,5-Dimethoxyamphetamine (DMA)

25

2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2)

30

2-(4-(Isopropylthio)-2,5-dimethoxyphenyl)ethanamine (2C-T-4)

30

3,4,5-Trimethoxyamphetamine

30

3,4-Methylenedioxyamphetamine (MDA)

55

3,4-Methylenedioxymethamphetamine (MDMA)

50

3,4-Methylenedioxy-N-ethylamphetamine (MDEA)

40

3,4-Methylenedioxy-N-methylcathinone (methylone)

40

3,4-Methylenedioxypyrovalerone (MDPV)

35

3-Fluoro-N-methylcathinone (3-FMC)

25

3-Methylfentanyl

30

3-Methylthiofentanyl

30

4-Bromo-2,5-dimethoxyamphetamine (DOB)

30

4-Bromo-2,5-dimethoxyphenethylamine (2-CB)

25

4-Chloro-alpha-pyrrolidinovalerophenone (4-chloro-alpha-PVP)

25

1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboximide (4CN-Cumyl-Butinaca)

25

4-Fluoroisobutyryl fentanyl

30

4-Fluoro-N-methylcathinone (4-FMC; Flephedrone)

25

4-Methyl-N-ethylcathinone (4-MEC)

25

4-Methoxyamphetamine

150

4-Methyl-2,5-dimethoxyamphetamine (DOM)

25

4-Methylaminorex

25

4-Methyl-N-methylcathinone (mephedrone)

45

4-Methyl-alpha-ethylaminopentiophenone (4-MEAP)

25

4-Methyl-alpha-pyrrolidinohexiophenone (MPHP)

25

4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP)

25

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol

50

5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol (cannabicyclohexanol or CP-47,497 C8-homolog)

40

5F-CUMYL-PINACA

25

5F-EDMB-PINACA

25

5F-MDMB-PICA

25

5F-AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide

25

5F-CUMYL-P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide)

25

5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)

30

5F-AMB (methyl 2-(1-(5-fluoropentyl)-1

H

-indazole-3-carboxamido)-3-methylbutanoate)

30

5F-APINACA; 5F-AKB48 (

N

-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide)

30

5-Fluoro-PB-22; 5F-PB-22

20

5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1

H-

indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone

25

5-Methoxy-3,4-methylenedioxyamphetamine

25

5-Methoxy-N,N-diisopropyltryptamine

25

5-Methoxy-N,N-dimethyltryptamine

25

AB-CHMINACA

30

AB-FUBINACA

50

AB-PINACA

30

ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)

30

Acetorphine

25

Acetyl Fentanyl

100

Acetyl-alpha-methylfentanyl

30

Acetyldihydrocodeine

30

Acetylmethadol

25

Acryl Fentanyl

25

ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)

50

AH-7921

30

Allylprodine

25

Alphacetylmethadol

25

Alpha

-

Ethyltryptamine

25

Alphameprodine

25

Alphamethadol

25

Alphaprodine

25

Alpha-Methylfentanyl

30

Alpha-Methylthiofentanyl

30

Alpha-Methyltryptamine (AMT)

25

Alpha-Pyrrolidinobutiophenone (α-PBP)

25

Alpha-Pyrrolidinoheptaphenone (PV8)

25

Alpha

-

Pyrrolidinohexanophenone (α-PHP)

25

Alpha-Pyrrolidinopentiophenone (α-PVP)

25

Aminorex

25

Anileridine

20

APINACA, AKB48 (

N

-(1-adamantyl)-1-pentyl-1

H

-indazole-3-carboxamide)

25

Benzethidine

25

Benzylmorphine

30

Betacetylmethadol

25

Beta-Hydroxy-3-methylfentanyl

30

Beta-Hydroxyfentanyl

30

Beta-Hydroxythiofentanyl

30

Betameprodine

25

Betamethadol

4

Betaprodine

25

Bufotenine

15

Butylone

25

Butyryl fentanyl

30

Cathinone

40

Clonitazene

25

Codeine methylbromide

30

Codeine-N-oxide

192

Cyclopentyl Fentanyl

30

Cyclopropyl Fentanyl

20

Cyprenorphine

25

Desomorphine

25

Dextromoramide

25

Diampromide

20

Diethylthiambutene

20

Diethyltryptamine

25

Difenoxin

9,200

Dihydromorphine

753,500

Dimenoxadol

25

Dimepheptanol

25

Dimethylthiambutene

20

Dimethyltryptamine

50

Dioxaphetyl butyrate

25

Dipipanone

25

Drotebanol

25

Ethylmethylthiambutene

25

Etonitazene

25

Etorphine

30

Etoxeridine

25

Fenethylline

30

Fentanyl related substances

600

FUB-144

25

FUB-AKB48

25

FUB-AMB, MMB-Fubinaca, AMB-Fubinaca

25

Furanyl fentanyl

30

Furethidine

25

Gamma Hydroxybutyric Acid

29,417,000

Heroin

45

Hydromorphinol

40

Hydroxypethidine

25

Ibogaine

30

Isobutyryl Fentanyl

25

JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)

35

JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)

45

JWH-073 (1-Butyl-3-(1-naphthoyl)indole)

45

JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl)indole)

30

JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)

30

JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)

35

JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)

30

JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)

30

JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)

30

Ketobemidone

30

Levomoramide

25

Levophenacylmorphan

25

Lysergic acid diethylamide (LSD)

40

MAB-CHMINACA; ADB-CHMINACA (

N

-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1

H

-indazole-3-carboxamide)

30

MDMB-CHMICA; MMB-CHMINACA (methyl 2-(1-(cyclohexylmethyl)-1

H

-indole-3-carboxamido)-3,3-dimethylbutanoate)

30

MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)

30

MMB-CHMICA (AMB-CHMICA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate

25

Marihuana

3,200,000

Mecloqualone

30

Mescaline

25

Methaqualone

60

Methcathinone

25

Methoxyacetyl fentanyl

30

Methyldesorphine

5

Methyldihydromorphine

25

Morpheridine

25

Morphine methylbromide

5

Morphine methylsulfonate

5

Morphine-N-oxide

150

MT-45

30

Myrophine

25

NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate

25

N,N-Dimethylamphetamine

25

Naphyrone

25

N-Ethyl-1-phenylcyclohexylamine

25

N-Ethyl-3-piperidyl benzilate

10

N-Ethylamphetamine

24

N

-

Ethylhexedrone

25

N

-

Ethylpentylone, ephylone

30

N-Hydroxy-3,4-methylenedioxyamphetamine

24

N-Methyl-3-Piperidyl Benzilate

30

Nicocodeine

25

Nicomorphine

25

Noracymethadol

25

Norlevorphanol

55

Normethadone

25

Normorphine

40

Norpipanone

25

Ocfentanil

25

Ortho-fluorofentanyl, 2-fluorofentanyl

30

Para-chloroisobutyryl fentanyl

30

Para-fluorofentanyl

25

Para-fluorobutyryl fentanyl

25

Para-methoxybutyryl fentanyl

30

Parahexyl

5

PB-22; QUPIC

20

Pentedrone

25

Pentylone

25

Phenadoxone

25

Phenampromide

25

Phenomorphan

25

Phenoperidine

25

Pholcodine

5

Piritramide

25

Proheptazine

25

Properidine

25

Propiram

25

Psilocybin

30

Psilocyn

50

Racemoramide

25

SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole)

45

SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole)

30

Tetrahydrocannabinols

384,460

Tetrahydrofuranyl fentanyl

15

Thebacon

25

Thiafentanil

25

Thiofentanyl

25

THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone)

30

Tilidine

25

Trimeperidine

25

UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

25

U-47700

30

Valeryl fentanyl

25

Schedule II

1-Phenylcyclohexylamine

15

1-Piperidinocyclohexanecarbonitrile

25

4-Anilino-N-phenethyl-4-piperidine (ANPP)

934,956

Alfentanil

3,260

Alphaprodine

25

Amobarbital

20,100

Amphetamine (for conversion)

14,137,578

Amphetamine (for sale)

44,330,000

Bezitramide

25

Carfentanil

20

Cocaine

73,090

Codeine (for conversion)

3,225,000

Codeine (for sale)

35,341,292

Dextropropoxyphene

35

Dihydrocodeine

156,713

Dihydroetorphine

25

Diphenoxylate (for conversion)

14,100

Diphenoxylate (for sale)

770,800

Ecgonine

78,439

Ethylmorphine

30

Etorphine hydrochloride

32

Fentanyl

934,956

Glutethimide

25

Hydrocodone (for conversion)

1,250

Hydrocodone (for sale)

33,997,285

Hydromorphone

3,512,651

Isomethadone

30

Levo-alphacetylmethadol (LAAM)

25

Levomethorphan

30

Levorphanol

31,730

Lisdexamfetamine

21,000,000

Meperidine

1,119,862

Meperidine Intermediate-A

30

Meperidine Intermediate-B

30

Meperidine Intermediate-C

30

Metazocine

15

Methadone (for sale)

25,619,700

Methadone Intermediate

27,673,600

Methamphetamine

1,224,109

[678,878 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 505,231 grams for methamphetamine mostly for conversion to a schedule III product; and 40,000 grams for methamphetamine (for sale).]

Methylphenidate

57,438,334

Metopon

25

Moramide-intermediate

25

Morphine (for conversion)

3,376,696

Morphine (for sale)

33,756,703

Nabilone

62,000

Norfentanyl

25

Noroxymorphone (for conversion)

22,044,741

Noroxymorphone (for sale)

376,000

Opium (powder)

250,000

Opium (tincture)

530,837

Oripavine

33,010,750

Oxycodone (for conversion)

725,998

Oxycodone (for sale)

65,667,554

Oxymorphone (for conversion)

28,204,371

Oxymorphone (for sale)

658,515

Pentobarbital

25,850,000

Phenazocine

25

Phencyclidine

35

Phenmetrazine

25

Phenylacetone

40

Piminodine

25

Racemethorphan

5

Racemorphan

5

Remifentanil

3,000

Secobarbital

172,100

Sufentanil

4,000

Tapentadol

13,447,541

Thebaine

59,284,070

List I Chemicals

Ephedrine (for conversion)

100

Ephedrine (for sale)

4,756,000

Phenylpropanolamine (for conversion)

14,100,000

Phenylpropanolamine (for sale)

16,590,000

Pseudoephedrine (for conversion)

1,000

Pseudoephedrine (for sale)

200,382,900

The Acting Administrator further proposes that APQ for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero.

Timothy J. Shea,

Acting Administrator.

[FR Doc. 2020-26443 Filed 11-30-20; 8:45 am]

BILLING CODE 4410-09-P